Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer

Sofia Lampaki, George Lazaridis, Konstantinos Zarogoulidis, Ioannis Kioumis, Antonis Papaiwannou, Katerina Tsirgogianni, Anastasia Karavergou, Theodora Tsiouda, Vasilis Karavasilis, Lonny Yarmus, Kaid Darwiche, Lutz Freitag, Antonios Sakkas, Angeliki Kantzeli, Sofia Baka, Wolfgang Hohenforst-Schmidt, Paul Zarogoulidis

Research output: Contribution to journalArticle

Abstract

Historical, the non-small cell lung cancer (NSCLC) was as a united disease entity and the chemotherapy to the metastatic cancer had limited results. Recent studies for the metastatic non-small cell lung cancer led to the ascertainment that the NSCLC does not constitute exclusively a disease entity, but different neoplasms guided from different molecular paths, different biological behavior and at extension requires different confrontation. Thus the new direction for the therapeutic approach of NSCLC is henceforth the most individualized approach based on the activated molecular paths of tumor. Distinct subtypes of NSCLC are driven by a specific genetic alteration, like EGFR, ALK, ROS1 or BRAF mutations, and these genetic alterations are sensitized to the inhibition of specific oncogenic pathways. The benefit from the use of tyrosine kinase inhibitors in patients with EGFR mutations it was confirmed by six randomized studies of phase III that investigated the role of gefitinib, erlotinib and afatinib. In these studies the response rates vary in the impressive percentages from 55% to 86% and were connected with a remarkable median progression free survival of approximately 8 to 13 months, and with better quality of life compared to that of chemotherapy. In early stages NSCLC is needed the individualization of systemic treatment in order to reduce toxicity that is observed in the classic chemotherapy and to impact outcome. The role of EGFR TKI's has been evaluated in the adjuvant chemotherapy in early stage resected NSCLC. The data from these studies suggest that adjuvant TKI therapy might not increase the overall survival, but delay the recurrences. Prospective trials restricted to EGFR or ALK driven NSCLC subsets potentially offering the opportunity for a definitive answer in early disease adjuvant setting (ALCHEMIST) or as induction treatment before stage III chemo-radiotherapy (RTOG 1210/Alliance 31101), are ongoing. Ongoing prospective trials may offer the opportunity for a definitive answer of the role of tyrosine kinase inhibitors in induction treatment before chemo-radiotherapy or in early disease adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)568-574
Number of pages7
JournalJournal of Cancer
Volume6
Issue number6
DOIs
StatePublished - 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Drug Therapy
Radiotherapy
Therapeutics
Neoplasms
Mutation
Adjuvant Chemotherapy
Disease-Free Survival
Quality of Life
Recurrence
Survival

Keywords

  • Egfr
  • Iressa
  • Lung cancer
  • Tarceva

ASJC Scopus subject areas

  • Oncology

Cite this

Lampaki, S., Lazaridis, G., Zarogoulidis, K., Kioumis, I., Papaiwannou, A., Tsirgogianni, K., ... Zarogoulidis, P. (2015). Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer. Journal of Cancer, 6(6), 568-574. https://doi.org/10.7150/jca.11893

Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer. / Lampaki, Sofia; Lazaridis, George; Zarogoulidis, Konstantinos; Kioumis, Ioannis; Papaiwannou, Antonis; Tsirgogianni, Katerina; Karavergou, Anastasia; Tsiouda, Theodora; Karavasilis, Vasilis; Yarmus, Lonny; Darwiche, Kaid; Freitag, Lutz; Sakkas, Antonios; Kantzeli, Angeliki; Baka, Sofia; Hohenforst-Schmidt, Wolfgang; Zarogoulidis, Paul.

In: Journal of Cancer, Vol. 6, No. 6, 2015, p. 568-574.

Research output: Contribution to journalArticle

Lampaki, S, Lazaridis, G, Zarogoulidis, K, Kioumis, I, Papaiwannou, A, Tsirgogianni, K, Karavergou, A, Tsiouda, T, Karavasilis, V, Yarmus, L, Darwiche, K, Freitag, L, Sakkas, A, Kantzeli, A, Baka, S, Hohenforst-Schmidt, W & Zarogoulidis, P 2015, 'Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer', Journal of Cancer, vol. 6, no. 6, pp. 568-574. https://doi.org/10.7150/jca.11893
Lampaki S, Lazaridis G, Zarogoulidis K, Kioumis I, Papaiwannou A, Tsirgogianni K et al. Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer. Journal of Cancer. 2015;6(6):568-574. https://doi.org/10.7150/jca.11893
Lampaki, Sofia ; Lazaridis, George ; Zarogoulidis, Konstantinos ; Kioumis, Ioannis ; Papaiwannou, Antonis ; Tsirgogianni, Katerina ; Karavergou, Anastasia ; Tsiouda, Theodora ; Karavasilis, Vasilis ; Yarmus, Lonny ; Darwiche, Kaid ; Freitag, Lutz ; Sakkas, Antonios ; Kantzeli, Angeliki ; Baka, Sofia ; Hohenforst-Schmidt, Wolfgang ; Zarogoulidis, Paul. / Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer. In: Journal of Cancer. 2015 ; Vol. 6, No. 6. pp. 568-574.
@article{56efa0b9449d4119bcc80e215f927b7c,
title = "Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer",
abstract = "Historical, the non-small cell lung cancer (NSCLC) was as a united disease entity and the chemotherapy to the metastatic cancer had limited results. Recent studies for the metastatic non-small cell lung cancer led to the ascertainment that the NSCLC does not constitute exclusively a disease entity, but different neoplasms guided from different molecular paths, different biological behavior and at extension requires different confrontation. Thus the new direction for the therapeutic approach of NSCLC is henceforth the most individualized approach based on the activated molecular paths of tumor. Distinct subtypes of NSCLC are driven by a specific genetic alteration, like EGFR, ALK, ROS1 or BRAF mutations, and these genetic alterations are sensitized to the inhibition of specific oncogenic pathways. The benefit from the use of tyrosine kinase inhibitors in patients with EGFR mutations it was confirmed by six randomized studies of phase III that investigated the role of gefitinib, erlotinib and afatinib. In these studies the response rates vary in the impressive percentages from 55{\%} to 86{\%} and were connected with a remarkable median progression free survival of approximately 8 to 13 months, and with better quality of life compared to that of chemotherapy. In early stages NSCLC is needed the individualization of systemic treatment in order to reduce toxicity that is observed in the classic chemotherapy and to impact outcome. The role of EGFR TKI's has been evaluated in the adjuvant chemotherapy in early stage resected NSCLC. The data from these studies suggest that adjuvant TKI therapy might not increase the overall survival, but delay the recurrences. Prospective trials restricted to EGFR or ALK driven NSCLC subsets potentially offering the opportunity for a definitive answer in early disease adjuvant setting (ALCHEMIST) or as induction treatment before stage III chemo-radiotherapy (RTOG 1210/Alliance 31101), are ongoing. Ongoing prospective trials may offer the opportunity for a definitive answer of the role of tyrosine kinase inhibitors in induction treatment before chemo-radiotherapy or in early disease adjuvant therapy.",
keywords = "Egfr, Iressa, Lung cancer, Tarceva",
author = "Sofia Lampaki and George Lazaridis and Konstantinos Zarogoulidis and Ioannis Kioumis and Antonis Papaiwannou and Katerina Tsirgogianni and Anastasia Karavergou and Theodora Tsiouda and Vasilis Karavasilis and Lonny Yarmus and Kaid Darwiche and Lutz Freitag and Antonios Sakkas and Angeliki Kantzeli and Sofia Baka and Wolfgang Hohenforst-Schmidt and Paul Zarogoulidis",
year = "2015",
doi = "10.7150/jca.11893",
language = "English (US)",
volume = "6",
pages = "568--574",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "6",

}

TY - JOUR

T1 - Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer

AU - Lampaki, Sofia

AU - Lazaridis, George

AU - Zarogoulidis, Konstantinos

AU - Kioumis, Ioannis

AU - Papaiwannou, Antonis

AU - Tsirgogianni, Katerina

AU - Karavergou, Anastasia

AU - Tsiouda, Theodora

AU - Karavasilis, Vasilis

AU - Yarmus, Lonny

AU - Darwiche, Kaid

AU - Freitag, Lutz

AU - Sakkas, Antonios

AU - Kantzeli, Angeliki

AU - Baka, Sofia

AU - Hohenforst-Schmidt, Wolfgang

AU - Zarogoulidis, Paul

PY - 2015

Y1 - 2015

N2 - Historical, the non-small cell lung cancer (NSCLC) was as a united disease entity and the chemotherapy to the metastatic cancer had limited results. Recent studies for the metastatic non-small cell lung cancer led to the ascertainment that the NSCLC does not constitute exclusively a disease entity, but different neoplasms guided from different molecular paths, different biological behavior and at extension requires different confrontation. Thus the new direction for the therapeutic approach of NSCLC is henceforth the most individualized approach based on the activated molecular paths of tumor. Distinct subtypes of NSCLC are driven by a specific genetic alteration, like EGFR, ALK, ROS1 or BRAF mutations, and these genetic alterations are sensitized to the inhibition of specific oncogenic pathways. The benefit from the use of tyrosine kinase inhibitors in patients with EGFR mutations it was confirmed by six randomized studies of phase III that investigated the role of gefitinib, erlotinib and afatinib. In these studies the response rates vary in the impressive percentages from 55% to 86% and were connected with a remarkable median progression free survival of approximately 8 to 13 months, and with better quality of life compared to that of chemotherapy. In early stages NSCLC is needed the individualization of systemic treatment in order to reduce toxicity that is observed in the classic chemotherapy and to impact outcome. The role of EGFR TKI's has been evaluated in the adjuvant chemotherapy in early stage resected NSCLC. The data from these studies suggest that adjuvant TKI therapy might not increase the overall survival, but delay the recurrences. Prospective trials restricted to EGFR or ALK driven NSCLC subsets potentially offering the opportunity for a definitive answer in early disease adjuvant setting (ALCHEMIST) or as induction treatment before stage III chemo-radiotherapy (RTOG 1210/Alliance 31101), are ongoing. Ongoing prospective trials may offer the opportunity for a definitive answer of the role of tyrosine kinase inhibitors in induction treatment before chemo-radiotherapy or in early disease adjuvant therapy.

AB - Historical, the non-small cell lung cancer (NSCLC) was as a united disease entity and the chemotherapy to the metastatic cancer had limited results. Recent studies for the metastatic non-small cell lung cancer led to the ascertainment that the NSCLC does not constitute exclusively a disease entity, but different neoplasms guided from different molecular paths, different biological behavior and at extension requires different confrontation. Thus the new direction for the therapeutic approach of NSCLC is henceforth the most individualized approach based on the activated molecular paths of tumor. Distinct subtypes of NSCLC are driven by a specific genetic alteration, like EGFR, ALK, ROS1 or BRAF mutations, and these genetic alterations are sensitized to the inhibition of specific oncogenic pathways. The benefit from the use of tyrosine kinase inhibitors in patients with EGFR mutations it was confirmed by six randomized studies of phase III that investigated the role of gefitinib, erlotinib and afatinib. In these studies the response rates vary in the impressive percentages from 55% to 86% and were connected with a remarkable median progression free survival of approximately 8 to 13 months, and with better quality of life compared to that of chemotherapy. In early stages NSCLC is needed the individualization of systemic treatment in order to reduce toxicity that is observed in the classic chemotherapy and to impact outcome. The role of EGFR TKI's has been evaluated in the adjuvant chemotherapy in early stage resected NSCLC. The data from these studies suggest that adjuvant TKI therapy might not increase the overall survival, but delay the recurrences. Prospective trials restricted to EGFR or ALK driven NSCLC subsets potentially offering the opportunity for a definitive answer in early disease adjuvant setting (ALCHEMIST) or as induction treatment before stage III chemo-radiotherapy (RTOG 1210/Alliance 31101), are ongoing. Ongoing prospective trials may offer the opportunity for a definitive answer of the role of tyrosine kinase inhibitors in induction treatment before chemo-radiotherapy or in early disease adjuvant therapy.

KW - Egfr

KW - Iressa

KW - Lung cancer

KW - Tarceva

UR - http://www.scopus.com/inward/record.url?scp=84930198574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930198574&partnerID=8YFLogxK

U2 - 10.7150/jca.11893

DO - 10.7150/jca.11893

M3 - Article

C2 - 26000049

AN - SCOPUS:84930198574

VL - 6

SP - 568

EP - 574

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 6

ER -